scholarly journals Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists

2016 ◽  
Vol 22 (6) ◽  
Author(s):  
Tiana Kazemi ◽  
Sabrina Martin ◽  
Scott Worswick
Keyword(s):  
Cutaneous Toxicity ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor

Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era

2020 ◽  
Vol 20 ◽  
Author(s):  
Giuseppe Lassandro ◽  
Valentina Palladino ◽  
Giovanni Carlo Del Vecchioa ◽  
Viviana Valeria Palmieri ◽  
Paola Carmela Corallo ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Treatment Options ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor ◽  
Related Quality ◽  
Health Related

Background and Objective: Immune thrombocytopenia (ITP) is a common bleeding disorder in childhood. The management of ITP in children is controversial, requiring personalized assessment of patients and therapeutic choices. Thrombopoietin receptor agonists (TPO-RAs), eltrombopag and romiplostim, have been shown to be safety and effective for the treatment of pediatric ITP. The aim of our research is defining the role of thrombopoietin receptor agonists in the management of pediatric ITP. Method: This review focuses on the use of TPO-RAs in pediatric ITP, in randomized trials and in clinical routine, highlighting their key role in management of the disease. Results: Eltrombopag and romiplostim appear effective treatment options for children with ITP. Several clinical studies have assessed that the use of TPO-RAs increases platelet count, decreases bleeding symptoms and improves health-related quality of life. Moreover, TPO-RAs are well tolerated with minor side effects. Conclusion: Although TPO-RAs long term efficacy and safety still require further investigations, their use is gradually expanding in clinical practice of children with ITP.

Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms

2012 ◽  
Vol 161 (1) ◽  
pp. 142-144 ◽  
Author(s):  
Nicola Polverelli ◽  
Francesca Palandri ◽  
Ilaria Iacobucci ◽  
Lucia Catani ◽  
Giovanni Martinelli ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Cross Resistance ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor

Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonists

2008 ◽  
Vol 18 (9) ◽  
pp. 3000-3006 ◽  
Author(s):  
Lawrence A. Reiter ◽  
Christopher S. Jones ◽  
William H. Brissette ◽  
Sandra P. McCurdy ◽  
Yuriy A. Abramov ◽  
...  
Keyword(s):  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Molecular Features ◽  
Thrombopoietin Receptor

Coronavirus disease 2019 in patients with chronic immune thrombocytopenia on thrombopoietin receptor agonists

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Nikola Pantic ◽  
Nada Suvajdzic-Vukovic ◽  
Marijana Virijevic ◽  
Zlatko Pravdic ◽  
Nikica Sabljic ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor ◽  
Chronic Immune Thrombocytopenia
Sign in / Sign up

Export Citation Format

Share Document